| Biomarker ID | 1750 |
| PMID | 30800682 |
| Year | 2019 |
| Biomarker | Neutrophil to Lymphocyte Ratio (NLR) |
| Biomarker Basis | Others |
| Biomolecule | Others |
| Source | Blood |
| Subjects | Humans |
| Regulation | Upregulated in PCa: Fold change mean(BPH: 1.470; PCa: 54.384) |
| Odds Ratio/Hazard Ratio/Relative Risk | Multivariate: HR: 4.57 (95% CI: 1.31-15.96) |
| Effect on Pathways | NA |
| Experiment | Overall Survival Vs No Overall Survival |
| Type of Biomarker | Prognostic |
| Cohort | 106 patients with CRPC were selected for the study. Patients were divided into 2 groups on the basis of NLR. higher NLR group (≥2.14; n=71) and lower NLR group (<2.14; n=35). All patients underwent Enzalutamide treatment |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.017 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |